Diligence memo · auto-generated · as of July 2, 2026
Aiko Biotechnology Inc
Aiko Biotechnology Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Aiko Biotechnology Inc operates in Pharmaceuticals, based in PORTLAND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aiko Biotechnology Inc has raised $1.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $850K on 2009-11-05.
Most recent recorded round closed around 2009-11-05.
Valuation (modeled)modeled
Provath models Aiko Biotechnology Inc at approximately $40M (range $476K–$456M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.43× the median modeled value of Pre-Seed Pharmaceuticals companies in 2007–2009 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 478 months.
Last raise 16.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 22% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 39% of those peers.
Closest niche peers: Entopica Therapeutics, Inc., Pneumoflex Systems Llc, Anterion Therapeutics, Inc., Ikano Therapeutics Inc., Ligon Discovery, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.